1
|
Chopei IV, Chubirko KI, Bychko MV, Hechko MM, Kedyk AV, Kogutych II. S-AMLODIPINE AS A MODERN EFFECTIVE ANTIHYPERTENSIVE AND AN ANTIANGINAL AGENT. WIADOMOSCI LEKARSKIE (WARSAW, POLAND : 1960) 2023; 76:2429-2434. [PMID: 38112360 DOI: 10.36740/wlek202311114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2023]
Abstract
OBJECTIVE The aim: Study of the clinical and hemodynamic effects of S-amlodipine in patients with arterial hypertension associated with coronary artery disease, in individuals with preserved LV systolic function. PATIENTS AND METHODS Materials and methods: The study includes 51 patients with arterial hypertension associated with coronary artery disease, who were treated with S-amlodipine. RESULTS Results: This study shows the high clinical effectiveness of the use of S-amlodipine in patients with arterial hypertension associated with coronary artery disease. We reveal that treatment of hypertensive patients with coronary artery disease with S-amlodipine leads to improvement of LV diastolic dysfunction, bringing it closer to normal values. CONCLUSION Conclusions: Clinical effectiveness was associated with positive changes in hemodynamics, and was expressed in the normalization of the left ventricle diastolic function parameters, about which indirectly indicates decreasing of end-diastolic pressure.
Collapse
|
2
|
Chenkual L, Lalchandani DS, Chaturvedi S, Mariyappan M, Porwal P. Development and validation of sensitive high‐performance liquid chromatography‐photodiode array method for determination of three sulfonated esters and
N
‐methyl‐
O
‐phenyldiamine dihydrochloride as potential genotoxic impurities in Amlodipine and Telmisartan fixed‐dose combination. SEPARATION SCIENCE PLUS 2022. [DOI: 10.1002/sscp.202200086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Laltanpuii Chenkual
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research‐Guwahati (NIPER‐G) Changsari India
| | - Dimple S. Lalchandani
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research‐Guwahati (NIPER‐G) Changsari India
| | - Sachin Chaturvedi
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research‐Guwahati (NIPER‐G) Changsari India
| | - Mahindran Mariyappan
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research‐Guwahati (NIPER‐G) Changsari India
| | - Pawan Porwal
- Department of Pharmaceutical Analysis National Institute of Pharmaceutical Education and Research‐Guwahati (NIPER‐G) Changsari India
| |
Collapse
|
3
|
Kim DK, Ahn JH, Lee KH, Kang S, Kim SS, Na JO, Park SD, Ahn KT, Lee J, Jung IH, Seo J, Choi WG. Ambulatory blood pressure response to S‐amlodipine in Korean adult patients with uncontrolled essential hypertension: A prospective, observational study. J Clin Hypertens (Greenwich) 2022; 24:350-357. [PMID: 35188327 PMCID: PMC8925000 DOI: 10.1111/jch.14442] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2021] [Revised: 01/19/2022] [Accepted: 01/29/2022] [Indexed: 11/30/2022]
Abstract
Although amlodipine is recommended as the first‐line therapy for the treatment of hypertension, its use is limited by its potential side effects. S‐amlodipine is expected to be able to minimize side effects of amlodipine with a similar antihypertensive effect by removing the malicious R‐chiral form. However, sustainable blood pressure control with S‐amlodipine has not been well established yet. The purpose of the current study was to evaluate ambulatory blood pressure (ABP) profiles before and after a 12‐week treatment of S‐amlodipine. Patients received once‐daily S‐amlodipine 2.5 or 5 mg. ABP during 24 hr and office blood pressure were measured at baseline and after the 12‐week treatment. Primary endpoints were changes of systolic and diastolic 24 hr ABP. After 12‐week S‐amlodipine treatment, mean systolic ABP (‐15.1 ± 16.2 mmHg, p < .001) and diastolic ABP (‐8.9 ± 9.8 mmHg, p < .001) were decreased significantly. Both daytime and night‐time mean systolic BP and diastolic BP were also significantly decreased after the 12‐week treatment. Global trough‐to‐peak ratio and smoothness index after 12‐week S‐amlodipine treatment were .75 and .79 for SBP and .65 and .61 for DBP, respectively. Age ≥65 years (hazard ratio [HR]: 3.13; 95% confidence interval [CI]: 1.67–14.3) and nonalcohol drinking (HR: 3.09; 95% CI: 1.34–7.17) were independent clinical factors for target ABP achievement. Adverse drug reactions (ADR) were developed in 16 (6.4%) patients, including two (.8%) cases of peripheral edema. In conclusion, this study demonstrated the efficacy and safety of S‐amlodipine in patients with uncontrolled essential hypertension.
Collapse
Affiliation(s)
- Dong Kyun Kim
- Department of Cardiology Chonnam National University Hospital Gwangju South Korea
| | - Joon Ho Ahn
- Department of Cardiology Chonnam National University Hospital Gwangju South Korea
- Department of Internal Medicine Chonnam National University Medical School Gwangju South Korea
| | - Ki Hong Lee
- Department of Cardiology Chonnam National University Hospital Gwangju South Korea
- Department of Internal Medicine Chonnam National University Medical School Gwangju South Korea
| | - Si‐Hyuck Kang
- Cardiovascular Center Department of Internal Medicine Seoul National University Bundang Hospital Seongnam South Korea
| | - Sung Soo Kim
- Department of Cardiology Chosun University Hospital Gwangju South Korea
| | - Jin Oh Na
- Department of Cardiology Korea University Guro Hospital Seoul South Korea
| | - Sang Don Park
- Department of Cardiology Inha University Hospital Incheon South Korea
| | - Kye Taek Ahn
- Department of Cardiology Chungnam National University Hospital Daejeon South Korea
| | - Jung‐Hee Lee
- Department of Cardiology Yeungnam University Medical Center Daegu South Korea
| | - In Hyun Jung
- Department of Cardiology Inje University Sanggye Paik Hospital Seoul South Korea
| | - Jongkwon Seo
- Department of Cardiology Inje University Sanggye Paik Hospital Seoul South Korea
| | - Woong Gil Choi
- Department of Internal Medicine Konkuk University School of Medicine Chungju South Korea
| |
Collapse
|
4
|
Mishra A, Harichandrakumar K, VS B, Satheesh S, Nair NS. Multivariate approach in analyzing medical data with correlated multiple outcomes: An exploration using ACCORD trial data. CLINICAL EPIDEMIOLOGY AND GLOBAL HEALTH 2021. [DOI: 10.1016/j.cegh.2021.100785] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
|
5
|
Wang J, Chia Y, Chen C, Park S, Hoshide S, Tomitani N, Kabutoya T, Shin J, Turana Y, Soenarta AA, Tay JC, Buranakitjaroen P, Nailes J, Van Minh H, Siddique S, Sison J, Sogunuru GP, Sukonthasarn A, Teo BW, Verma N, Zhang Y, Wang T, Kario K. What is new in the 2018 Chinese hypertension guideline and the implication for the management of hypertension in Asia? J Clin Hypertens (Greenwich) 2020; 22:363-368. [DOI: 10.1111/jch.13803] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2019] [Accepted: 11/20/2019] [Indexed: 01/17/2023]
Affiliation(s)
- Ji‐Guang Wang
- Department of Hypertension Centre for Epidemiological Studies and Clinical Trials The Shanghai Institute of Hypertension Shanghai Key Laboratory of Hypertension Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
| | - Yook‐Chin Chia
- Department of Medical Sciences School of Healthcare and Medical Sciences Sunway University Bandar Sunway Ehsan Malaysia
- Department of Primary Care Medicine Faculty of Medicine University of Malaya Kuala Lumpur Malaysia
| | - Chen‐Huan Chen
- Department of Medicine School of Medicine National Yang‐Ming University Taipei Taiwan
| | - Sungha Park
- Division of Cardiology Yonsei Health System Cardiovascular Hospital Seoul Korea
| | - Satoshi Hoshide
- Division of Cardiovascular Medicine Department of Medicine Jichi Medical University School of Medicine Tochigi Japan
| | - Naoko Tomitani
- Division of Cardiovascular Medicine Department of Medicine Jichi Medical University School of Medicine Tochigi Japan
| | - Tomoyuki Kabutoya
- Division of Cardiovascular Medicine Department of Medicine Jichi Medical University School of Medicine Tochigi Japan
| | - Jinho Shin
- Faculty of Cardiology Service Hanyang University Medical Center Seoul Korea
| | - Yuda Turana
- Faculty of Medicine and Health Sciences Atma Jaya Catholic University of Indonesia Jakarta Indonesia
| | - Arieska Ann Soenarta
- Department of Cardiology and Vascular Medicine Faculty of Medicine University of Indonesia‐National Cardiovascular Center Jakarta Indonesia
| | - Jam Chin Tay
- Department of General Medicine Tan Tock Seng Hospital Singapore Singapore
| | - Peera Buranakitjaroen
- Department of Medicine Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand
| | - Jennifer Nailes
- University of the East Ramon Magsaysay Memorial Medical Center Inc. Quezon City Philippines
| | - Huynh Van Minh
- Department of Internal Medicine University of Medicine and Pharmacy Hue University Hue Vietnam
| | | | - Jorge Sison
- Section of CardiologyDepartment of MedicineMedical Center Manila Manila Philippines
| | - Guru Prasad Sogunuru
- MIOT International Hospital Chennai India
- College of Medical Sciences Kathmandu University Bharatpur Nepal
| | - Apichard Sukonthasarn
- Cardiology Division Department of Internal Medicine Faculty of Medicine Chiang Mai University Chiang Mai Thailand
| | - Boon Wee Teo
- Division of Nephrology Department of Medicine Yong Loo Lin School of Medicine Singapore Singapore
| | - Narsingh Verma
- Department of Physiology King George's Medical University Lucknow India
| | - Yu‐Qing Zhang
- Divisions of Hypertension and Heart Failure Chinese Academy of Medical Sciences and Peking Union Medical College Fu Wai Hospital Beijing China
| | - Tzung‐Dau Wang
- Department of Internal Medicine National Taiwan University College of Medicine Taipei City Taiwan
| | - Kazuomi Kario
- Division of Cardiovascular Medicine Department of Medicine Jichi Medical University School of Medicine Tochigi Japan
| |
Collapse
|
6
|
Huang Q, Sheng C, Li Y, Dou Y, Zheng M, Zhu Z, Wang J. A randomized controlled trial on the blood pressure–lowering effect of amlodipine and nifedipine‐GITS in sustained hypertension. J Clin Hypertens (Greenwich) 2019; 21:648-657. [PMID: 30973207 DOI: 10.1111/jch.13543] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Revised: 03/02/2019] [Accepted: 03/08/2019] [Indexed: 11/30/2022]
Affiliation(s)
- Qi‐Fang Huang
- Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Department of Hypertension, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
| | - Chang‐Sheng Sheng
- Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Department of Hypertension, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
| | - Yan Li
- Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Department of Hypertension, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
| | - Yu Dou
- Jiangsu Province Hospital for Governmental Employees Nanjing China
| | | | - Zhi‐Ming Zhu
- Chongqing Hypertension Institute, Department of Hypertension and Endocrinology, Daping Hospital The Third Military Medical University Chongqing China
| | - Ji‐Guang Wang
- Centre for Epidemiological Studies and Clinical Trials, The Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Department of Hypertension, Ruijin Hospital Shanghai Jiaotong University School of Medicine Shanghai China
| | | |
Collapse
|
7
|
Xu SK, Huang QF, Zeng WF, Sheng CS, Li Y, Wang JG. A randomized multicenter study on ambulatory blood pressure and arterial stiffness in patients treated with valsartan/amlodipine or nifedipine GITS. J Clin Hypertens (Greenwich) 2018; 21:252-261. [PMID: 30582271 DOI: 10.1111/jch.13457] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2018] [Revised: 10/05/2018] [Accepted: 10/23/2018] [Indexed: 12/28/2022]
Abstract
In a pre-specified subgroup analysis of a 12-week randomized multicenter study, we investigated effects of valsartan/amlodipine 80/5 mg single-pill combination (n = 75) and nifedipine GITS 30 mg (n = 75) on ambulatory blood pressure (BP) and arterial stiffness assessed by brachial-ankle pulse wave velocity (PWV) in patients with uncontrolled hypertension. At week 12, the between-treatment mean differences in systolic/diastolic BP were smaller for 24-hour and daytime (-2.1/-1.7 and -2.0/-1.5 mm Hg, respectively, P ≥ 0.22) but greater (P < 0.01) for nighttime (-4.0/-2.8 mm Hg, P ≤ 0.09), especially in sustained uncontrolled hypertension (-5.0/-4.1 mm Hg, P ≤ 0.04) and non-dippers (-6.5/-3.7 mm Hg, P ≤ 0.07), in favor of valsartan/amlodipine. At week 12, PWV was significantly reduced from baseline by valsartan/amlodipine (n = 59, P < 0.0001) but not nifedipine (n = 59, P = 0.06). The changes in PWV were significantly associated with that in ambulatory systolic BP and pulse pressure in the nifedipine (P ≤ 0.0008) but not valsartan/amlodipine group (P ≥ 0.57), with a significant interaction (P ≤ 0.045). The valsartan/amlodipine combination was more efficacious than nifedipine GITS in lowering nighttime BP in sustained uncontrolled hypertension and non-dippers, and in lowering arterial stiffness independent of BP lowering.
Collapse
Affiliation(s)
- Shao-Kun Xu
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Qi-Fang Huang
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Wei-Fang Zeng
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Chang-Sheng Sheng
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Yan Li
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - Ji-Guang Wang
- Department of Hypertension, Centre for Epidemiological Studies and Clinical Trials, Shanghai Key Laboratory of Hypertension, The Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
| |
Collapse
|
8
|
S-Amlodipine: An Isomer with Difference-Time to Shift from Racemic Amlodipine. Int J Hypertens 2018; 2018:8681792. [PMID: 29887996 PMCID: PMC5985099 DOI: 10.1155/2018/8681792] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Accepted: 04/08/2018] [Indexed: 12/21/2022] Open
Abstract
Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.
Collapse
|
9
|
Şen S, Demir M, Yiğit Z, Üresin AY. Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy. J Cardiovasc Pharmacol Ther 2018; 23:318-328. [PMID: 29649885 PMCID: PMC5974697 DOI: 10.1177/1074248418769054] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
The aim of the present study was to evaluate the efficacy and safety of S-amlodipine 2.5 and 5 mg/d in patients with hypertension who were treatment-naive or previously received antihypertensive monotherapy. During the 8-week treatment period, all patients received S-amlodipine 2.5 mg/d for the first 4 weeks, followed by S-amlodipine 5 mg/d for the second 4 weeks. For efficacy assessments, ambulatory and office blood pressure (BP) measurements were performed during the baseline, fourth-week, and eighth-week visits. For safety assessments, all adverse events and abnormal laboratory findings were recorded. This study is registered with ClinicalTrials.gov (NCT03038451). Of 43 patients evaluated at the screening visit, 33 were enrolled. In the treatment-naive arm, significant reductions in both office and ambulatory systolic BP (SBP) and diastolic BP (DBP) were observed with S-amlodipine 2.5 mg/d and additional significant reductions were achieved with dose titration (S-amlodipine 5 mg/d). At the end of the study, the rate of the treatment-naive patients with BP under control (SBP/DBP <140/90 mm Hg) was 53% with S-amlodipine 2.5 mg and increased to 78% with S-amlodipine 5 mg. For the noninferiority evaluation, S-amlodipine 2.5 and 5 mg/d treatments were generally noninferior to both office and ambulatory BP levels achieved with the medications that the patients received before participating in the study. Five nonserious adverse events likely to be associated with the study drug were observed. No serious adverse event was encountered. Consequently, S-amlodipine can be suggested as an effective and safe treatment option for patients with hypertension.
Collapse
Affiliation(s)
- Selçuk Şen
- 1 Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Meral Demir
- 1 Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| | - Zerrin Yiğit
- 2 Department of Cardiology, Institute of Cardiology, Istanbul University, Istanbul, Turkey
| | - Ali Yağız Üresin
- 1 Department of Medical Pharmacology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| |
Collapse
|